What Is PGT-M (Preimplantation Genetic Testing for Monogenic Disorders)?
PGT-M (Preimplantation Genetic Testing for Monogenic Disorders), formerly known as PGD (Preimplantation Genetic Diagnosis), is an advanced genetic screening technique used during in vitro fertilization (IVF) to test embryos for specific inherited, single-gene (monogenic) disorders before implantation. This test helps identify embryos carrying known disease-causing gene mutations, allowing intended parents or people trying to conceive to select embryos without that particular disorder for transfer.
The PGT-M process involves creating embryos in a laboratory setting, biopsying a few cells from each embryo at an early developmental stage, and analyzing these cells using specialized molecular techniques to determine whether the embryo carries the targeted mutation. PGT-M is widely used for families at risk of passing on genetic conditions such as cystic fibrosis, BRCA hereditary cancers, Huntington disease, sickle cell anemia, and others.
Key Takeaways
- PGT-M screens embryos for specific inherited single-gene (monogenic) disorders before implantation during IVF.
- The technique was previously known as PGD (Preimplantation Genetic Diagnosis).
- PGT-M is particularly useful for couples or individuals with a known risk of transmitting a single-gene disorder like cystic fibrosis, Huntington disease, or BRCA mutations.
- An IVF cycle and embryo biopsy are required for PGT-M—natural conception cannot use this technology.
- Testing is highly accurate but depends on proof of the exact mutation in family members.
- Using PGT-M can reduce the risk of having a child affected by specific genetic conditions.
- The cost of PGT-M is significant and may not be covered by insurance in many locations.
- The process involves custom probe development for each family's specific mutation, which can take weeks.
- PGT-M differs from PGT-A, which tests for chromosomal aneuploidy, not single-gene disorders.
- Ethical support and genetic counseling are strongly recommended for families considering PGT-M.
Table of Contents
- What Is PGT-M (Preimplantation Genetic Testing for Monogenic Disorders)?
- How Does PGT-M Work in Fertility Treatment?
- Which Genetic Conditions Can PGT-M Test For?
- Who Should Consider PGT-M?
- What Is the PGT-M Process Step by Step?
- How Accurate Is PGT-M?
- PGT-M vs PGT-A: What's the Difference?
- Is PGT-M Safe for Embryos?
- PGT-M Cost and Insurance Coverage
- Custom Probe Development for PGT-M
- Benefits and Limitations of PGT-M
- Risks, Limitations, and Ethical Considerations
- When to Consult a Fertility Specialist or Genetic Counselor
- Frequently Asked Questions About PGT-M
- References and Further Reading
- Disclaimer
How Does PGT-M Work in Fertility Treatment?
PGT-M is an early-embryo genetic testing technique used within the context of IVF (in vitro fertilization). The process requires:
Stepwise Mechanism
-
Parental Genetic Testing
- The process begins with blood or saliva tests from both genetic parents (and sometimes extended family) to determine the exact mutation present in the family.
- The laboratory designs a customized genetic “probe” to precisely detect this mutation in embryos.
-
IVF and Embryo Creation
- Eggs are retrieved from the ovaries and fertilized with sperm in the lab to create embryos.
-
Embryo Biopsy
- At the blastocyst stage (typically 5-7 days after fertilization), a specialist removes a few cells from each embryo (usually from the trophectoderm, which becomes the placenta).
- This minimally invasive biopsy does not remove cells from the developing fetus part of the embryo.
-
Genetic Analysis
- The biopsied cells are sent to a genetics lab.
- The custom probe detects whether the embryo carries, does not carry, or is a carrier for the target mutation.
-
Embryo Selection
- The results guide which embryos are suitable for transfer—those without the targeted disorder can be prioritized.
Key Point: Only embryos without the specific disease-causing mutation (or, in some cases, only carriers) will be recommended for transfer.
PGT-M “At a Glance” Quick Facts Table
| Aspect | PGT-M (PGD) Description |
|---|---|
| Purpose | Detect single-gene mutations in embryos |
| Timing | Performed during IVF at blastocyst/preimplantation stage |
| Sample | Biopsied embryonic cells (usually at day 5–7 blastocyst) |
| Conditions Tested | Monogenic disorders (CF, BRCA, Huntington, etc.) |
| Success Rate | Very high technical accuracy (>98% for many tested genes) |
| Suitability | Intended parents at risk for known inherited disorders |
| Not Suitable For | General population or unknown genetic risks |
| Other Names | PGD, single-gene PGT |
Which Genetic Conditions Can PGT-M Test For?
PGT-M is tailored to screen embryos for specific single-gene disorders where the families have a known risk. Some well-known conditions include:
- Cystic fibrosis (CF): One of the most common uses for PGT-M, as it is a prevalent inherited disorder.
- BRCA1/BRCA2 mutations: Known to increase risk of breast and ovarian cancers; embryos can be screened for hereditary cancer risk.
- Huntington disease: An autosomal dominant neurological disorder; PGT-M can eliminate transmission to offspring.
- Sickle cell anemia
- Thalassemia
- Tay-Sachs disease
- Duchenne muscular dystrophy
- Fragile X syndrome
- Hemophilia
- Spinal muscular atrophy
- Marfan syndrome
- Dozens of other monogenic inherited conditions
Did you know? Over 600 monogenic diseases can be evaluated by PGT-M if the specific mutation is known in a family.
Disorders Requiring “Custom Probe PGT-M”
For rare conditions, the genetic laboratory may need extra time to develop a personalized molecular “probe” specific to your family’s variant. This step is vital to ensure accurate detection.
Who Should Consider PGT-M?
PGT-M is generally recommended for:
- People or couples with a known, inherited single-gene mutation who wish to avoid transmission to their child.
- Those who have a child, sibling, or close relative affected by a monogenic disorder.
- Carriers of autosomal recessive disorders (e.g., cystic fibrosis) where both partners are carriers.
- Those with autosomal dominant mutations (e.g., Huntington disease, Marfan syndrome, BRCA1/2).
- Individuals or couples planning family building via egg, sperm, or embryo donation, when relevant to the donor’s genetics.
PGT-M is not typically used in the absence of a concrete familial mutation or history.
What Is the PGT-M Process Step by Step?
-
Family Genetic Consultation
- Meet with a genetic counselor or medical geneticist for a genealogy review and panel testing.
-
Confirming the Pathogenic Variant
- DNA samples from parents (and sometimes affected siblings/relatives) are analyzed to pinpoint the pathogenic gene variant.
-
Custom Probe Development
- The genetics lab develops a custom probe for the family’s specific mutation (may take 2–6 weeks).
-
IVF Cycle
- Ovarian stimulation, egg retrieval, fertilization (using sperm), and embryo culture.
-
Embryo Biopsy
- At the blastocyst stage, 3-7 cells are biopsied from each embryo.
-
Genetic Testing (Lab Analysis)
- Biopsied DNA is analyzed for the presence or absence of the mutation.
-
Embryo Freezing
- Embryos are almost always cryopreserved while awaiting PGT-M results.
-
Embryo Selection and Transfer
- Only embryos without the mutation (or, if desired, carrier embryos) are considered for transfer to the uterus.
Key Point: The entire PGT-M process, from probe development to embryo transfer, may take several weeks to months due to the need for bespoke lab work.
How Accurate Is PGT-M?
Technical Accuracy
- PGT-M’s technical accuracy is extremely high—over 98-99% for most well-characterized gene mutations, especially when both biological parents' genetics are available for comparison PGT-M technical accuracy.
- Residual risks for misdiagnosis, sample mishandling, or technical limitations are very low but not zero.
Limitations
- Allele dropout: Very rarely, the tested allele is missed, leading to a false-negative or false-positive.
- Embryonic mosaicism: Some embryos may have mixed genetic profiles across different cells, complicating interpretation.
- PGT-M cannot test for all types of mutations or for unknown genetic variations.
Did you know? To further reduce misdiagnosis risk, confirmatory prenatal genetic testing (CVS or amniocentesis) is still recommended after successful pregnancy.
PGT-M vs PGT-A: What's the Difference?
Definitions
- PGT-M (“M” for monogenic) screens for specific single-gene mutations—for example, cystic fibrosis or BRCA.
- PGT-A (“A” for aneuploidy) screens for abnormal chromosome numbers, like Down syndrome, but does not detect inherited single-gene disorders.
Comparison Table
| Feature | PGT-M | PGT-A |
|---|---|---|
| Detects | Specific gene mutations | Chromosome number abnormalities |
| Use case | Inherited, single-gene disease risk | General IVF to improve implantation |
| Custom lab work needed | Yes (custom probe) | No (standard panel) |
| Examples | CF, BRCA, Huntington | Trisomy 21 (Down syndrome), others |
| Also previously called | PGD | N/A |
Key Point: Many clinics offer PGT-M and PGT-A in combination to check both the specific inherited condition and overall embryo chromosome health.
Is PGT-M Safe for Embryos?
- Embryo Biopsy: Modern blastocyst biopsy techniques (sampling 5–7 cells from the outer trophectoderm layer) minimize risk to the developing embryo, with no increase in rates of birth defects or developmental delay in large studies PGT embryo safety.
- Embryos are frozen after biopsy, with transfer in a subsequent cycle.
Key Point: While the procedure is considered safe, a small risk of embryo loss exists during biopsy. Discuss risks with your fertility clinic.
PGT-M Cost and Insurance Coverage
Typical Costs
- In the United States, PGT-M generally costs $4,000–$8,000 USD in addition to the standard IVF cycle costs PGT-M costs.
- Custom probe development may incur additional fees, especially for rare mutations.
- Medication, IVF procedures, and storage are billed separately.
Insurance Coverage
- Coverage is highly variable. Some plans may cover PGT-M for severe hereditary disease, but most do not.
- Genetic counseling and documentation proving medical necessity may help with insurance appeals.
| Cost Component | Typical Range (USD) |
|---|---|
| PGT-M lab work | $4,000–$8,000 |
| Custom probe dev. | $1,000–$3,000 extra |
| IVF cycle | $12,000–$20,000 |
| Embryo freezing | $750–$1,500 |
Custom Probe Development for PGT-M
- Each family's unique gene mutation requires a custom probe, a complex piece of molecular technology designed to latch onto the exact mutation during analysis.
- The lab may require DNA samples from parents, affected relatives, or even grandparents to design the most accurate test.
- Probe design can take 2–6 weeks or more, so plan for this in your family-building timeline.
Benefits and Limitations of PGT-M
Benefits
- Prevention of inherited genetic disease: Major reduction in transmitting targeted single-gene disorders to children.
- Proactive family planning: Empowers people to grow their families with added confidence.
- Information for carrier parents: Enables decisions when both partners are carriers.
Limitations
- Not all diseases covered: Only known, single-gene (monogenic) conditions with a defined mutation.
- IVF required: Not possible with natural conception.
- Costly: Financial burden is significant and often not covered by insurance.
- Some embryos may still be unsuitable: Some cycles may yield few or no embryos free of the mutation, particularly in autosomal dominant conditions.
Risks, Limitations, and Ethical Considerations
- Residual misdiagnosis risk: Though low, occurs due to technical limitations.
- Embryo wastage: Discarding embryos with mutations raises ethical concerns for some.
- Psychological impact: Emotional burden from possible “no embryo suitable” results.
- Non-medical trait testing: Testing for non-disease traits is controversial and widely discouraged by medical organizations Ethical concerns in PGT.
| Concern | Risk/Issue | Mitigation |
|---|---|---|
| False negatives/positives | <2% risk; technical errors | Use experienced labs; prenatal confirmation recommended |
| Embryo loss during biopsy | Very low risk (<1% per blastocyst) | Modern biopsy, skilled practitioners |
| Ethical concerns | Embryo selection, potential social controversy | Genetic counseling, ethical review |
Did you know? All reputable clinics require pre-PGT-M genetic counseling to ensure families understand the technology’s benefits and limits.
When to Consult a Fertility Specialist or Genetic Counselor
People should consider consulting an REI (Reproductive Endocrinology and Infertility specialist) or a certified genetic counselor if:
- They have a personal or family history of a serious inherited disease.
- Carrier status is identified in routine pre-pregnancy screening.
- Both partners are related, increasing rare disorder risk.
- They are considering IVF for any reason and have a known genetic risk.
Genetic counselors can clarify which testing is possible, interpret results, and help with emotional decision-making.
Frequently Asked Questions About PGT-M
What does PGT-M mean in fertility and IVF?
PGT-M (Preimplantation Genetic Testing for Monogenic Disorders) is a type of embryo testing used during IVF to screen for inherited single-gene diseases before an embryo is implanted. It helps identify embryos that do not carry specific disease-causing gene mutations, allowing families at risk of transmitting genetic conditions to make informed choices about embryo transfer.
What’s the difference between PGT-M and PGT-A?
PGT-M tests for specific inherited single-gene mutations (such as CF or BRCA mutations), while PGT-A checks for chromosome number abnormalities (like Down syndrome). Both use similar embryo biopsy methods but target different genetic risks.
Which conditions can PGT-M test for?
PGT-M can detect hundreds of monogenic diseases, including cystic fibrosis, sickle cell anemia, Huntington disease, BRCA1/2 hereditary cancer mutations, thalassemia, and more. The process requires prior identification of the exact mutation in the parents or family.
How accurate is PGT-M for single-gene diseases?
Technical accuracy is greater than 98% for most diseases, especially when robust family genetic information is provided. However, small risks of false negatives and lab error exist, so prenatal diagnostic confirmation after a successful pregnancy is recommended.
What is the step-by-step process for PGT-M?
PGT-M involves genetic counseling and family mutation confirmation, custom probe development, IVF, embryo biopsy, genetic analysis, and then selection of embryos without the target illness for transfer.
How long does the PGT-M process take?
Custom probe development usually takes 2–6 weeks, while the IVF and biopsy workflow adds another few weeks. The full process from initial consultation to embryo transfer can take 2–3 months.
Is PGT-M the same as PGD?
Yes—PGT-M replaces the older term PGD (Preimplantation Genetic Diagnosis) but refers to the same process of single-gene embryo testing. The new naming system aims for greater clarity and standardization.
Can PGT-M detect BRCA mutations?
Absolutely. PGT-M can be used to detect BRCA1 and BRCA2 mutations associated with hereditary breast and ovarian cancer syndromes, helping carriers avoid passing the elevated cancer risk to children.
How does PGT-M for cystic fibrosis work?
For cystic fibrosis (CF), PGT-M can identify embryos that are affected, unaffected, or carriers of the known CFTR gene mutation in the family, greatly reducing the chance of having a child with CF.
What does it cost to have PGT-M?
In the United States, total costs (including custom probe) are generally $5,000–$10,000, in addition to IVF cycle and medication fees. Insurance coverage varies; for most people, the cost is out-of-pocket.
Is PGT-M safe for embryos?
Current blastocyst biopsy methods are considered safe, with no increased risk of major birth defects. A very small chance of embryo injury exists, but this is rare.
Are there ethical concerns with PGT-M?
Ethical debate surrounds embryo selection and disposal, especially regarding which conditions justify testing. However, most professional organizations support PGT-M for serious inherited disease prevention but not for non-medical trait selection.
Can you do PGT-M without IVF?
No—PGT-M requires IVF to create embryos outside the body so they can be biopsied before transfer. Natural conception does not allow preimplantation testing.
How reliable are PGT-M labs?
Reputable, accredited genetics labs offering PGT-M must comply with strict standards. Patients should ask their fertility clinic about validation rates and lab experience.
Do I need both parents' DNA for PGT-M?
Yes—testing the biological parents (and ideally an affected family member) is essential for developing the custom probe and ensuring accuracy.
Is PGT-M covered by insurance?
Coverage is limited and depends on the severity of the disorder, employer plan, and region. Some policies may cover PGT-M for conditions like cystic fibrosis, but appeals and medical necessity letters are often needed.
What is a “custom probe” in PGT-M and why does it matter?
A custom probe is a lab-developed set of molecular tools tailored to your family's specific gene mutation. This probe ensures highly accurate detection but adds time and cost to the process.
What should I discuss with my clinician before considering PGT-M?
It's important to talk about family history, prior children with genetic disorders, timeframes, emotional readiness, costs, insurance, and the possibility of not creating mutation-free embryos.
References and Further Reading
- Zamani Esteki M, et al. "Concurrent whole-genome haplotyping and copy-number profiling of single cells." https://pubmed.ncbi.nlm.nih.gov/32054689/
- He G, et al. "Embryo biopsy, genetic testing and offspring health." https://pubmed.ncbi.nlm.nih.gov/31585423/
- Rechitsky S, et al. "Preimplantation genetic testing for monogenic diseases: perspectives and recent advancements." https://pubmed.ncbi.nlm.nih.gov/33853690/
- Tur-Kaspa I, et al. "Genetic testing of embryos: basic concepts, indications, and clinical experience." https://pubmed.ncbi.nlm.nih.gov/24883287/
- Ethics Committee of the American Society for Reproductive Medicine. "Use of preimplantation genetic testing for monogenic defects (PGT-M) for adult-onset conditions: a committee opinion." https://pubmed.ncbi.nlm.nih.gov/33965097/
- European Society of Human Reproduction and Embryology (ESHRE) Preimplantation Genetic Diagnosis Consortium Data Collection. https://www.eshre.eu/
- Human Fertilisation & Embryology Authority (HFEA)—PGT-M information page. https://www.hfea.gov.uk/
- American Society for Reproductive Medicine (ASRM)—Genetics and IVF. https://www.asrm.org/topics/topics-index/genetics-and-ivf/
- National Society of Genetic Counselors PGT Resource. https://www.nsgc.org/page/preimplantation-genetic-testing-pgt
Disclaimer
This article is for informational and educational purposes only and does not constitute medical or mental health advice. It is not a substitute for speaking with a qualified healthcare provider, licensed therapist, or other professional who can consider your individual situation.
